Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission
| Autor: | Wenjie Ma, Fengzhu Li, Lin Zhou, Weihui Sun, Anhua Hao, Cuicui Ren, Zhi Dong, Lei Ma, Lili Wang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Pediatrics medicine.medical_specialty Hepatitis B virus mother-neonatal transmission Observational Study Antiviral Agents 03 medical and health sciences Young Adult 0302 clinical medicine Hepatitis B Chronic Pregnancy Telbivudine long-term efficacy and safety Medicine Humans 030212 general & internal medicine Pregnancy Complications Infectious Hepatitis B immune globulin postpartum bleeding business.industry Infant Newborn Wechsler Adult Intelligence Scale General Medicine Hepatitis B Viral Load medicine.disease Infectious Disease Transmission Vertical Treatment Outcome 030220 oncology & carcinogenesis Apgar score Female business Viral load medicine.drug Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 |
| Popis: | To observe the efficacy of telbivudine in chronic hepatitis B (CHB) women with high viral load during pregnancy and the long-term effects on intelligence, growth, and development of the newborns. A total of 87 patients were included. Forty-two patients received telbivudine orally 600 mg per day and treatment initiated from 12 weeks after gestation until the 12th postpartum week. Forty-five patients were untreated according to principle of informed consent. All infants received injection of hepatitis B immune globulin (HBIG; 200 IU) and were vaccinated with recombinant HBV vaccine. Wechsler preschool intelligence scale was used to assess mental and neuropsychological developments of these children till they were 6 years old. Data including serum HBV DNA viral load, Apgar score, and scores of Wechsler preschool intelligence scale were analyzed and compared. Levels of both serum HBV DNA and ALT in patients who received telbivudine were significantly decreased at the 12th week after delivery, compared with baseline levels (P .05). Serum HBV DNA and ALT levels at the 12th week after delivery in the telbivudine group were significantly lower than those of patients without telbivudine (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|